Project Grant R01AI200666
- Federal Grant Award Summary Duke University's Office of Research Administration received a Project Grant award of $806,623 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective May 29, 2026, with completion targeted for April 30, 2027. The award supports structural and kinetic research aimed at elucidating the association transition states and intermediates governing HIV-1 broadly neutralizing...
- Federal Project Grant Award Summary Duke University's Office of Research Administration received a $106,164 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective April 1, 2026 through March 31, 2028. This award supports investigator-initiated research examining the role of HLA-E-VL9 (Human Leukocyte Antigen-E complexed with a conserved viral peptide) and related antibodies in...
- Federal Project Grant Award Summary Duke University's Office of Research Administration received a $161,500 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded April 1, 2026, with completion targeted for March 31, 2028. The award funds the development of new genetic tools—specifically novel Cre and CreERT2 transgenic mouse models—for selective targeting and study of plasma cells...
- Federal Project Grant Award Summary Duke University's Office of Research Administration received a $1,171,275 project grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded May 8, 2026, with completion targeted for April 30, 2027. The grant funds research and development of a combined T cell and B cell therapeutic countermeasure designed to achieve functional HIV-1 cure through sustained viral...
- Federal Project Grant Award Summary Duke University's Office of Research Administration received a $208,875 Project Grant from the National Institute of Allergy and Infectious Diseases under the Allergy and Infectious Diseases Research program (CFDA 93.855) for the period August 1, 2025 through July 31, 2028. The grant supports research and development of a multivalent messenger ribonucleic acid (mRNA) HIV vaccine designed to elicit broadly neutralizing antibodies (BNAbs) targeting conserved...
- Federal Project Grant Award Summary Duke University's Office of Research Administration has received a $829,735 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded April 1, 2026, with completion targeted for March 31, 2031. This research initiative focuses on the discovery and optimization of broadly protective neutralizing antibodies against Merbecovirus (MERB), a genus of...
- Grant Award Summary Duke University received a $791,661 Project Grant from the National Institute of Allergy and Infectious Diseases under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective August 1, 2025, through July 31, 2030. The award supports research focused on developing an HIV-1 vaccine utilizing integrase-defective lentiviral vectors (IDLVs) to deliver HIV and SIV antigens. The research aims to optimize vaccine delivery platforms and multi-antigen strategies...
- Federal Grant Award Summary Duke University received a $237,831 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded May 22, 2026, with completion targeted for April 30, 2028. The research project, conducted at Duke's Durham, North Carolina facility, investigates the role of MESH1 protein in regulating RNA sensing through nucleotide metabolism. The research will produce biochemical...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded $121,182 to the University of California, San Diego under the Allergy and Infectious Diseases Research program (CFDA 93.855) on December 5, 2025, with a completion date of February 3, 2028. This Project Grant supports research investigating the roles of vaccine perturbations on germinal center dynamics as they relate to human immunodeficiency virus (HIV) vaccine development. The research will...
- Federal Cooperative Agreement Summary Duke University's Office of Research Administration received a $1,239,565 Cooperative Agreement award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective August 20, 2025, with completion scheduled for June 30, 2030. This award funds research to elucidate the mechanisms of early-life immunity associated with HIV-1 vaccine-induced neutralizing antibody...
Duke University's Office of Research Administration received a $783,701 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective May 22, 2026, through April 30, 2031. The grant supports investigator-initiated research to elucigate the mechanisms governing B cell evolution and plasma cell differentiation in the context of broadly neutralizing antibody (bNAb) development against HIV. The research utilizes a reproducible knockin mouse model system to test hypotheses about how precursor bNAb B cells develop into mature plasma cells capable of producing durable, protective antibodies in blood serum. The primary deliverables include high-throughput antibody sequencing of plasma cells from immunized mice, production and characterization of selected antibody sequences, and experimental measurement of HIV neutralization capacity across multiple viral strains. Through this integrated approach, the research aims to identify which individual plasma cells contribute to total serum neutralization capacity and determine critical evolutionary events during B cell maturation. These findings are intended to advance understanding of antibody generation mechanisms and inform the development of improved immunotherapies and medical countermeasures for HIV infection.Federal Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $783.7k | 5/25/26 |